Quantbot Technologies LP Acquires Shares of 92,888 Certara, Inc. (NASDAQ:CERT)

Quantbot Technologies LP acquired a new stake in shares of Certara, Inc. (NASDAQ:CERT - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 92,888 shares of the company's stock, valued at approximately $1,088,000. Quantbot Technologies LP owned 0.06% of Certara at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Blue Trust Inc. purchased a new stake in shares of Certara in the second quarter worth approximately $26,000. Innealta Capital LLC purchased a new stake in Certara in the second quarter worth $36,000. KBC Group NV lifted its position in shares of Certara by 48.2% during the third quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Certara in the second quarter worth about $152,000. Finally, Algert Global LLC purchased a new position in Certara in the 2nd quarter worth about $156,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CERT has been the topic of a number of research analyst reports. UBS Group upgraded shares of Certara from a "neutral" rating to a "buy" rating and set a $16.00 target price on the stock in a research note on Friday, September 27th. Barclays reduced their price objective on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a report on Thursday, November 7th. Finally, Robert W. Baird lowered their target price on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, November 5th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $15.92.

Certara Stock Down 0.5 %

CERT stock traded down $0.06 during trading on Friday, reaching $11.21. 497,170 shares of the company traded hands, compared to its average volume of 1,045,216. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business has a 50 day simple moving average of $10.81 and a 200 day simple moving average of $13.00. Certara, Inc. has a 12 month low of $9.41 and a 12 month high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. During the same period last year, the firm earned $0.06 earnings per share. Certara's revenue was up 10.7% compared to the same quarter last year. Analysts forecast that Certara, Inc. will post 0.28 EPS for the current year.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the sale, the insider now directly owns 99,704 shares of the company's stock, valued at $1,125,658.16. This represents a 33.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares in the company, valued at $552,503.73. The trade was a 9.75 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by company insiders.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.